Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
Zacks Investment Research | Feb 13, 2020 09:12PM ET
This week, AbbVie (NYSE:ABBV) and Allergan (NYSE:AGN) reported fourth-quarter results. Meanwhile, a phase II/III investigator-led study in inherited Alzheimer's disease conducted on Roche (OTC:RHHBY) and Lilly’s (NYSE:LLY) candidates, gantenerumab and solanezumab, respectively, failed to meet the primary endpoint.
Recap of the Week’s Most Important Stories:
Earnings Update: Both Keytruda plus chemotherapy, as first-line treatment for metastatic triple-negative breast cancer (mTNBC), met the primary endpoint. Interim data from the pivotal KEYNOTE-355 study showed that Keytruda plus chemotherapy significantly improved progression-free survival, one of the dual primary endpoints, compared to chemotherapy alone in these patients. The independent Data Monitoring Committee recommended that the study will continue without modifications to evaluate the other dual primary endpoint of overall survival.
The NYSE ARCA Pharmaceutical Index declined 1.2% in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.